Cantor Fitzgerald analyst Alethia Young maintained a Buy rating on TG Therapeutics (TGTX) today and set a price target of $17. The company’s shares opened today at $8.47.
Young noted:
“We think both umbralisib and ublituximab are clinically de-risked, but investors remain cautious on market potential. Although the PI3K commercial landscape in particular has been historically challenging due to class safety issues, we think umbralisib’s safety profile is differentiated. We think TG has a potentially best-in-class PI3K and other pipeline assets that make attractive oncology and autoimmune combinations. We think safe, late-stage assets with proven activity will allow for many future novel combinations that would be upside to our current valuation. We think investors will give more credit to the stock as the Ph3 data accrues across multiple indications.”
According to TipRanks.com, Young is a 5-star analyst with an average return of 8.9% and a 50.9% success rate. Young covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Vertex Pharmaceuticals, and Sarepta Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for TG Therapeutics with a $14 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $16 and a one-year low of $3.32. Currently, TG Therapeutics has an average volume of 2.15M.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib.
